Enrollment Completed for the SAD Part 1 of Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals completed enrollment for Phase 1 clinical trial of DA-1726, a dual oxyntomodulin analog agonist for obesity treatment, with 45 participants in 5 cohorts. The trial aims to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of DA-1726. Top-line data from the trial's SAD Part 1 is expected in Q3 2024, and from MAD Part 2 in Q1 2025. DA-1726 showed superior weight loss in pre-clinical data compared to other drugs, potentially positioning it as a best-in-class obesity drug.